Embecta Corp. (NASDAQ:EMBC) Short Interest Update

Embecta Corp. (NASDAQ:EMBC) saw a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 1,850,000 shares, a decrease of 17.0% from the February 28th total of 2,230,000 shares. Based on an average daily trading volume, of 535,900 shares, the days-to-cover ratio is presently 3.5 days. Currently, 3.5% of the shares of the stock are short sold.

Insiders Place Their Bets

In related news, Director Milton Mayo Morris sold 3,100 shares of Embecta stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $16.38, for a total transaction of $50,778.00. Following the completion of the transaction, the director now directly owns 36,133 shares of the company’s stock, valued at approximately $591,858.54. The trade was a 7.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 0.42% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Embecta

Hedge funds and other institutional investors have recently made changes to their positions in the business. Siemens Fonds Invest GmbH purchased a new stake in Embecta in the 4th quarter valued at about $77,000. Ameriflex Group Inc. acquired a new position in shares of Embecta in the 4th quarter valued at about $53,000. Mackenzie Financial Corp grew its holdings in shares of Embecta by 4.4% during the 4th quarter. Mackenzie Financial Corp now owns 40,956 shares of the company’s stock worth $846,000 after purchasing an additional 1,743 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Embecta by 16.8% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 164,279 shares of the company’s stock worth $3,392,000 after purchasing an additional 23,611 shares in the last quarter. Finally, WBI Investments LLC purchased a new position in Embecta in the fourth quarter valued at approximately $247,000. Hedge funds and other institutional investors own 93.83% of the company’s stock.

Embecta Stock Down 0.4 %

Shares of Embecta stock traded down $0.05 during trading on Wednesday, hitting $12.58. 151,143 shares of the company were exchanged, compared to its average volume of 440,124. The firm has a 50 day moving average price of $15.02 and a 200 day moving average price of $16.23. The stock has a market capitalization of $731.33 million, a price-to-earnings ratio of 12.58, a P/E/G ratio of 0.78 and a beta of 1.27. Embecta has a fifty-two week low of $9.93 and a fifty-two week high of $21.48.

Embecta (NASDAQ:EMBC) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.65 EPS for the quarter, topping analysts’ consensus estimates of $0.45 by $0.20. Embecta had a net margin of 5.25% and a negative return on equity of 19.22%. Analysts predict that Embecta will post 2.85 earnings per share for the current year.

Embecta Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 14th. Stockholders of record on Friday, February 28th were issued a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a dividend yield of 4.77%. The ex-dividend date of this dividend was Friday, February 28th. Embecta’s dividend payout ratio (DPR) is 60.00%.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.